Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529)
Abstract Introduction Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases is potentially curable by radical treatment. This study aimed to evaluate the efficacy and safety of chemoradiotherapy (CRT) for thoracic disease, including the primary lesion and lymph node metastases, combine...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Radiation Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13014-024-02577-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850281940288012288 |
|---|---|
| author | Takaaki Tokito Kazuhiko Yamada Hidenobu Ishii Yuichi Takiguchi Go Saito Koichi Minato Hisao Imai Hiroshi Tanaka Satoru Miura Kageaki Watanabe Yoshifusa Koreeda Akira Ono Naoki Furuya Toshihiro Misumi Kazushige Hayakawa Etsuyo Ogo Hiroaki Okamoto |
| author_facet | Takaaki Tokito Kazuhiko Yamada Hidenobu Ishii Yuichi Takiguchi Go Saito Koichi Minato Hisao Imai Hiroshi Tanaka Satoru Miura Kageaki Watanabe Yoshifusa Koreeda Akira Ono Naoki Furuya Toshihiro Misumi Kazushige Hayakawa Etsuyo Ogo Hiroaki Okamoto |
| author_sort | Takaaki Tokito |
| collection | DOAJ |
| description | Abstract Introduction Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases is potentially curable by radical treatment. This study aimed to evaluate the efficacy and safety of chemoradiotherapy (CRT) for thoracic disease, including the primary lesion and lymph node metastases, combined with local consolidative therapy (LCT) for oligometastases. Methods This was a multicenter Phase II trial for patients with Stage IV NSCLC with oligometastases for whom CRT for thoracic disease was feasible. The treatment procedures included CRT containing platinum-doublet for thoracic disease and LCT for oligometastases within 8 weeks of starting or completing CRT. The primary endpoint was the 2-year survival rate. Results We enrolled 19 patients between June 2016 and May 2020. The median age was 68 (range: 51–74) years. Twelve patients had adenocarcinoma, and 6 had squamous cell carcinoma. The metastasis sites included the brain, bone, adrenal gland, lung, and cervical lymph node (n = 9, 7, 2, 1, and 1, respectively). All patients completed CRT concurrently with LCT for all oligometastases. There were 11 partial responses, resulting in a response rate of 58% (95% confidence interval [CI] 33.5–79.7%). Median progression-free survival and overall survival were 8.6 (95% CI 7.0–10.2) and 42.1 (80% CI 13.6–not reached) months, respectively. The 2-year survival rate was 68.4% (80% CI 52.6%–79.9%). Fourteen patients (74%) showed progression with newly observed lesions. There were no severe adverse events, and toxicities were tolerable. Conclusion Chemotherapy in combination with aggressive LCT for NSCLC with oligometastases might extend survival and achieve local control. Clinical trial registration: University Hospital Medical Information Network, Japan (protocol identification number: UMIN000022431, first registration date: 01/JUN/2016). |
| format | Article |
| id | doaj-art-b405b6d186df4a00a0557c1ad75f6802 |
| institution | OA Journals |
| issn | 1748-717X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Radiation Oncology |
| spelling | doaj-art-b405b6d186df4a00a0557c1ad75f68022025-08-20T01:48:08ZengBMCRadiation Oncology1748-717X2025-01-0120111010.1186/s13014-024-02577-5Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529)Takaaki Tokito0Kazuhiko Yamada1Hidenobu Ishii2Yuichi Takiguchi3Go Saito4Koichi Minato5Hisao Imai6Hiroshi Tanaka7Satoru Miura8Kageaki Watanabe9Yoshifusa Koreeda10Akira Ono11Naoki Furuya12Toshihiro Misumi13Kazushige Hayakawa14Etsuyo Ogo15Hiroaki Okamoto16Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of MedicineDivision of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of MedicineDivision of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of MedicineDepartment of Medical Oncology, Graduate School of Medicine, Chiba University HospitalDepartment of Respirology, Graduate School of Medicine, Chiba University HospitalDivision of Respiratory Medicine, Gunma Prefectural Cancer CenterDivision of Respiratory Medicine, Gunma Prefectural Cancer CenterDepartment of Internal Medicine, Niigata Cancer Center HospitalDepartment of Internal Medicine, Niigata Cancer Center HospitalDepartment of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome HospitalDepartment of Respiratory Medicine, Minamikyusyu National HospitalDivision of Thoracic Oncology, Shizuoka Cancer CenterDivision of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of MedicineDepartment of Data Science, National Cancer Center Hospital EastDepartment of Radiation Oncology, National Hospital Organization Disaster Medical CenterRadiation Oncology Center, Kurume UniversityDepartment of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen’s HospitalAbstract Introduction Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases is potentially curable by radical treatment. This study aimed to evaluate the efficacy and safety of chemoradiotherapy (CRT) for thoracic disease, including the primary lesion and lymph node metastases, combined with local consolidative therapy (LCT) for oligometastases. Methods This was a multicenter Phase II trial for patients with Stage IV NSCLC with oligometastases for whom CRT for thoracic disease was feasible. The treatment procedures included CRT containing platinum-doublet for thoracic disease and LCT for oligometastases within 8 weeks of starting or completing CRT. The primary endpoint was the 2-year survival rate. Results We enrolled 19 patients between June 2016 and May 2020. The median age was 68 (range: 51–74) years. Twelve patients had adenocarcinoma, and 6 had squamous cell carcinoma. The metastasis sites included the brain, bone, adrenal gland, lung, and cervical lymph node (n = 9, 7, 2, 1, and 1, respectively). All patients completed CRT concurrently with LCT for all oligometastases. There were 11 partial responses, resulting in a response rate of 58% (95% confidence interval [CI] 33.5–79.7%). Median progression-free survival and overall survival were 8.6 (95% CI 7.0–10.2) and 42.1 (80% CI 13.6–not reached) months, respectively. The 2-year survival rate was 68.4% (80% CI 52.6%–79.9%). Fourteen patients (74%) showed progression with newly observed lesions. There were no severe adverse events, and toxicities were tolerable. Conclusion Chemotherapy in combination with aggressive LCT for NSCLC with oligometastases might extend survival and achieve local control. Clinical trial registration: University Hospital Medical Information Network, Japan (protocol identification number: UMIN000022431, first registration date: 01/JUN/2016).https://doi.org/10.1186/s13014-024-02577-5OligometastasisLocal consolidative therapyNon-small cell lung cancer |
| spellingShingle | Takaaki Tokito Kazuhiko Yamada Hidenobu Ishii Yuichi Takiguchi Go Saito Koichi Minato Hisao Imai Hiroshi Tanaka Satoru Miura Kageaki Watanabe Yoshifusa Koreeda Akira Ono Naoki Furuya Toshihiro Misumi Kazushige Hayakawa Etsuyo Ogo Hiroaki Okamoto Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529) Radiation Oncology Oligometastasis Local consolidative therapy Non-small cell lung cancer |
| title | Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529) |
| title_full | Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529) |
| title_fullStr | Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529) |
| title_full_unstemmed | Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529) |
| title_short | Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529) |
| title_sort | single arm multicenter phase ii study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage iv non small cell lung carcinoma with oligometastases cure oligo torg1529 |
| topic | Oligometastasis Local consolidative therapy Non-small cell lung cancer |
| url | https://doi.org/10.1186/s13014-024-02577-5 |
| work_keys_str_mv | AT takaakitokito singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT kazuhikoyamada singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT hidenobuishii singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT yuichitakiguchi singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT gosaito singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT koichiminato singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT hisaoimai singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT hiroshitanaka singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT satorumiura singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT kageakiwatanabe singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT yoshifusakoreeda singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT akiraono singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT naokifuruya singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT toshihiromisumi singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT kazushigehayakawa singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT etsuyoogo singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 AT hiroakiokamoto singlearmmulticenterphaseiistudyonaggressivelocalconsolidativetherapyincombinationwithsystemicchemotherapyforstageivnonsmallcelllungcarcinomawitholigometastasescureoligotorg1529 |